EE04929B1 - Mitteinterageeruvate ravimite kombinatsioon, farmatseutiline ravimkoostis ja farmatseutiline pakend, mis sisaldab (E) -7-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)amino]primidiin-5-l]-(3R ,3S)-3,5-dihdrokshept-6-eenhapet ja P450 - Google Patents

Mitteinterageeruvate ravimite kombinatsioon, farmatseutiline ravimkoostis ja farmatseutiline pakend, mis sisaldab (E) -7-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)amino]primidiin-5-l]-(3R ,3S)-3,5-dihdrokshept-6-eenhapet ja P450

Info

Publication number
EE04929B1
EE04929B1 EEP200100406A EEP200100406A EE04929B1 EE 04929 B1 EE04929 B1 EE 04929B1 EE P200100406 A EEP200100406 A EE P200100406A EE P200100406 A EEP200100406 A EE P200100406A EE 04929 B1 EE04929 B1 EE 04929B1
Authority
EE
Estonia
Prior art keywords
methyl
fluorophenyl
pyrimidine
isopropyl
amino
Prior art date
Application number
EEP200100406A
Other languages
English (en)
Estonian (et)
Inventor
induktorit v?i substraati ja sellise koostise kasutamine
Raza Ali
Stuart Pears John
Gerard Hutchinson Howard
Schneck Dennis
Baba Takahiko
Touchi Akira
Yamaguchi Yoshitaka
Original Assignee
Astrazeneca Ab
Shionogi & Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE04929(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9902593.4A external-priority patent/GB9902593D0/en
Priority claimed from GBGB9921064.3A external-priority patent/GB9921064D0/en
Priority claimed from GBGB9921063.5A external-priority patent/GB9921063D0/en
Application filed by Astrazeneca Ab, Shionogi & Co. Ltd. filed Critical Astrazeneca Ab
Publication of EE200100406A publication Critical patent/EE200100406A/xx
Publication of EE04929B1 publication Critical patent/EE04929B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EEP200100406A 1999-02-06 2000-02-01 Mitteinterageeruvate ravimite kombinatsioon, farmatseutiline ravimkoostis ja farmatseutiline pakend, mis sisaldab (E) -7-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)amino]primidiin-5-l]-(3R ,3S)-3,5-dihdrokshept-6-eenhapet ja P450 EE04929B1 (et)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9902593.4A GB9902593D0 (en) 1999-02-06 1999-02-06 Drug combinations
GBGB9921064.3A GB9921064D0 (en) 1999-09-08 1999-09-08 Drug combination
GBGB9921063.5A GB9921063D0 (en) 1999-09-08 1999-09-08 Therapy
PCT/GB2000/000278 WO2000045817A1 (en) 1999-02-06 2000-02-01 Drug combinations comprising (e) -7 - [4 -(4 -fluorophenyl) -6 - isopropyl -2 - [methyl (methylsulfonyl) amino] pyrimidin -5 -yl] (3r,5s) -3,5 - dihydroxyhept -6 - enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4

Publications (2)

Publication Number Publication Date
EE200100406A EE200100406A (et) 2002-10-15
EE04929B1 true EE04929B1 (et) 2007-12-17

Family

ID=27269637

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100406A EE04929B1 (et) 1999-02-06 2000-02-01 Mitteinterageeruvate ravimite kombinatsioon, farmatseutiline ravimkoostis ja farmatseutiline pakend, mis sisaldab (E) -7-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)amino]primidiin-5-l]-(3R ,3S)-3,5-dihdrokshept-6-eenhapet ja P450

Country Status (28)

Country Link
US (3) US6982157B1 (cs)
EP (1) EP1185274B1 (cs)
JP (2) JP2002536331A (cs)
KR (2) KR20010101790A (cs)
CN (1) CN1165310C (cs)
AR (1) AR029333A1 (cs)
AT (1) ATE282415T1 (cs)
AU (1) AU767304B2 (cs)
BR (1) BR0007999A (cs)
CA (1) CA2358632C (cs)
CZ (1) CZ301296B6 (cs)
DE (1) DE60015965T2 (cs)
EE (1) EE04929B1 (cs)
EG (1) EG23858A (cs)
ES (1) ES2232418T3 (cs)
GB (1) GB0000710D0 (cs)
ID (1) ID30485A (cs)
IL (1) IL144715A0 (cs)
IS (1) IS2337B (cs)
MX (1) MXPA01007905A (cs)
MY (1) MY130606A (cs)
NO (1) NO320745B1 (cs)
NZ (1) NZ512982A (cs)
PL (1) PL198034B1 (cs)
PT (1) PT1185274E (cs)
TR (1) TR200102228T2 (cs)
TW (1) TWI282738B (cs)
WO (1) WO2000045817A1 (cs)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
RS50406B (sr) 2001-01-26 2009-12-31 Schering Corporation, Upotreba supstituisanih jedinjenja azetidinona za lečenje sitosterolemije
CN100509058C (zh) 2001-01-26 2009-07-08 先灵公司 过氧化物酶体增殖物激活受体(ppar)活化剂和甾醇吸收抑制剂的组合药以及对于血管适应症的治疗
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
ATE345793T1 (de) 2001-09-21 2006-12-15 Schering Corp Behandlung von xanthom mittels azetidinon- derivate als hemmer der sterol absorption
JP2006508188A (ja) 2002-11-06 2006-03-09 シェーリング　コーポレイション 脱髄の処置のためのコレステロール吸収インヒビター
WO2004081003A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholeterolemia
MXPA05009503A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
MXPA05009502A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US7658944B2 (en) 2003-10-10 2010-02-09 Lifecycle Pharma A/S Solid dosage form comprising a fibrate
US9173847B2 (en) 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2008509154A (ja) 2004-08-06 2008-03-27 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 新規なスタチン薬剤組成物および関連治療方法
US20090162316A1 (en) * 2005-07-05 2009-06-25 Harvard University Liver targeted conjugates
EA015682B1 (ru) * 2005-12-20 2011-10-31 Лек Фармасьютиклз Д.Д. Фармацевтическая композиция
US20080109252A1 (en) * 2006-11-08 2008-05-08 Lafountain Andrea Predicting patient compliance with medical treatment
US20120130202A1 (en) * 2010-11-24 2012-05-24 Fujitsu Limited Diagnosis and Monitoring of Musculoskeletal Pathologies
AU2019285170A1 (en) * 2018-06-14 2021-01-28 Astrazeneca Uk Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition
NZ785375A (en) 2019-07-31 2025-07-25 Intas Pharmaceuticals Ltd Pharmaceutical composition comprising hmg-coa reductase inhibitors and fenofibrate
WO2024223797A1 (en) 2023-04-28 2024-10-31 Institut National de la Santé et de la Recherche Médicale Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
EP0521417B1 (de) * 1991-07-02 1994-11-23 Joh. A. Benckiser GmbH Zusammenfaltbare Vorratsflasche
JP3852621B2 (ja) * 1992-01-21 2006-12-06 あすか製薬株式会社 血管内皮細胞機能改善剤
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
US6576660B1 (en) * 1997-10-31 2003-06-10 Arch Development Corporation Methods and compositions for regulation of 5-α-reductase activity

Also Published As

Publication number Publication date
ID30485A (id) 2001-12-13
MY130606A (en) 2007-07-31
US6982157B1 (en) 2006-01-03
CN1338936A (zh) 2002-03-06
KR20010101790A (ko) 2001-11-14
WO2000045817A1 (en) 2000-08-10
TWI282738B (en) 2007-06-21
TR200102228T2 (tr) 2002-03-21
CA2358632A1 (en) 2000-08-10
CZ20012844A3 (cs) 2001-11-14
KR20060117381A (ko) 2006-11-16
EP1185274B1 (en) 2004-11-17
NO320745B1 (no) 2006-01-23
AU767304B2 (en) 2003-11-06
JP2002536331A (ja) 2002-10-29
BR0007999A (pt) 2001-11-06
PL198034B1 (pl) 2008-05-30
ES2232418T3 (es) 2005-06-01
CA2358632C (en) 2008-10-28
DE60015965T2 (de) 2006-01-05
NO20013811D0 (no) 2001-08-03
CZ301296B6 (cs) 2010-01-06
NO20013811L (no) 2001-10-02
AR029333A1 (es) 2003-06-25
IS6009A (is) 2001-07-17
ATE282415T1 (de) 2004-12-15
JP2007277267A (ja) 2007-10-25
IS2337B (is) 2008-02-15
AU2121800A (en) 2000-08-25
CN1165310C (zh) 2004-09-08
PT1185274E (pt) 2005-03-31
EE200100406A (et) 2002-10-15
GB0000710D0 (en) 2000-03-08
MXPA01007905A (es) 2003-06-04
IL144715A0 (en) 2002-06-30
HK1041817A1 (en) 2002-07-26
DE60015965D1 (de) 2004-12-23
EG23858A (en) 2007-11-18
US20090042911A1 (en) 2009-02-12
US20060040969A1 (en) 2006-02-23
NZ512982A (en) 2003-08-29
PL364780A1 (en) 2004-12-13
EP1185274A1 (en) 2002-03-13

Similar Documents

Publication Publication Date Title
EE04929B1 (et) Mitteinterageeruvate ravimite kombinatsioon, farmatseutiline ravimkoostis ja farmatseutiline pakend, mis sisaldab (E) -7-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)amino]primidiin-5-l]-(3R ,3S)-3,5-dihdrokshept-6-eenhapet ja P450
EE05586B1 (et) Farmatseutiline kompositsioon, mis sisaldab (E)-7-[4-(4-fluorofenüül)-6-isopropüül-2-[metüül(metüül-sulfonüül)amino]pürimidiin-5-üül]-(3R,5S)-3,5-dihüdroksühept-6-eenhapet v?i selle farmatseutiliseltaktsepteeritavat soola, millel on valguse toime ees
NZ525419A (en) Pharmaceutical formulations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid
HUP0204051A3 (en) Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid, process for their preparation and pharmaceutical compositions containing them
IL155919A (en) (e) - 7 - [4 - (4 - fluorophenyl) - 6 - isopropyl - 2 - [methyl ( methylsulfonyl) amino] pyrimidin - 5 - yl] (3r, 5s) - dihydroxyhept - 6 - enoic acid, or a pharmaceutically acceptable salt thereof, for use as a medicament for the treatment of heterozygous familial hypercholesterolemia
HUP0302980A3 (en) Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moeties as inhibitors of protein junkinases and pharmaceutical compositions containing them
HUP0201275A3 (en) Novel use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts and pharmaceutical composition containing the compound
EE200300371A (et) Peroraalselt ja paikselt manustatavad farmatseutilised kopmositsioonid
HK1040924A1 (zh) 降膽固醇劑的應用
HUP0402092A3 (en) Use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts for preparation of pharmaceutical compositions
WO2005107809A3 (en) Antimycobacterial pharmaceutical composition comprising an antitubercular drug
HUP0002459A3 (en) Salts of optically active sulfoxide derivative, pharmaceutical compositions containing them and use thereof
NZ308110A (en) Polymorphs of lesopitron dihydrochloride, ie 2-[4-[4-[4- (chloropyrazole-1-yl)butyl]-1-piperazinyl]pyrimidine, and its hydrated forms, preparation and pharmaceutical compositions
ITMI991524A0 (it) Composizione farmaceutica costituita da un sale di paroxetina ed una s ostanza poliidrossilata

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231